Hepatic transporters and
drug metabolizing
enzymes (
DMEs) play important roles in the pharmacological effects and (or) side-effects of many drugs, and are regulated by several mediators, including
neurotransmitters. This work aimed to investigate whether serum levels of
5-hydroxytryptamine (5-HT) affected the expression of hepatic transporters or
DMEs. The expression of hepatic transporters was assessed using the Western-blot technique in a 2,4,6-trinitrobenzenesulfonic-acid-induced rat model of post-infectious
irritable bowel syndrome (PI-IBS), in which serum levels of
5-HT were significantly elevated. To further clarify the underlying mechanism, the
5-HT precursor
5-hydroxytryptophan (5-HTP) and the
5-HT depleting agent parachlorophenylalanine (pCPA) were applied to adjust serum levels of
5-HT. Serum levels of
5-HT were measured using LC-MS/MS; the expression of hepatic transporters,
DMEs, and
nuclear receptors were examined by Western-blot technique. Our results showed that in PI-IBS rats the expression of
multidrug resistance protein 2 (Mrp2) was significantly decreased, while colonic enterochromaffin cell density and serum levels of
5-HT were all significantly increased. Moreover,
5-HTP treatment significantly increased serum levels of
5-HT and decreased the expression of Mrp2 and
glycoprotein P (P-gp), whereas treatment with pCPA markedly decreased serum levels of
5-HT and increased the expression of Mrp2 and P-gp. Our results indicated that serum
5-HT regulates the expression of Mrp2 and P-gp, and the underlying mechanism may be related to the altered expression of the
nuclear receptor constitutive androstane receptor (CAR).